In This Article:
Press Release
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
-
CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON’s net sales.
-
ETON confirmed its commitment to finalize the development and manufacturing steps of its adrenal insufficiency product line, including both the CROSSJECT Formulation, referred to ET-800, and the life-changing crisis management product-ZENEO® Hydrocortisone, to capture a significant share of a >$200M market opportunity in the US alone.
-
Product filings expected from 2H 2026 onward.
Dijon, France March 25, 2025 (7.30AM CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, an emergency injectable for the management of epilepsy crises, announces positive updates in its collaboration with US endocrinology leader ETON PHARMACEUTICALS, Inc. (“ETON”). In June 2021, ETON in-licensed commercialization rights to ZENEO® Hydrocortisone for the US and Canadian markets.
As part of the development of ZENEO® Hydrocortisone, CROSSJECT developed a unique, and proprietary ready-to-use liquid formulation of hydrocortisone. This formulation represents a significant innovation in the US market where formulations, such as PFIZER’s Solu-Cortef®, are effective solutions, yet require more than ten steps for reconstitution and mixing. As part of the joint effort to bring new solutions to adrenal insufficiency patients, ETON will develop and commercialize this CROSSJECT Formulation as a superior alternative to current injectables. CROSSJECT will earn a high single digit royalty on ETON’s net sales of such product, referred to as ET-800 in ETON’s pipeline, and retains the right to commercialize the product outside the US and Canada. ETON expects to gain a significant share of that hospital market opportunity for hydrocortisone injectables estimated at $100 million.
In parallel, ETON confirmed, in its latest investor presentation dated March 18 2025, its commitment to ZENEO® Hydrocortisone as a life-changing solution for adrenal insufficiency crises. Future development and manufacturing milestones, under CROSSJECT’s plans, are expected from early 2026 onward. ETON early evaluation of the market opportunity of ZENEO® Hydrocortisone exceeds $100 million.